The Journal of Urology
Volume 178, Issue 6 , Pages 2378-2384, December 2007

A Phase II Trial of Bortezomib and Prednisone for Castration Resistant Metastatic Prostate Cancer

Departments of Medicine (Genitourinary Oncology Service), Radiology and Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center and Department of Medicine, Weill Medical College of Cornell University, New York, New York

Received 5 April 2007 published online 15 October 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Study received Memorial Sloan-Kettering Cancer Center institutional review board approval.

 Supported by Millennium Pharmaceuticals, National Cancer Institute Grants CA102544 and CA05826, Prostate Cancer Foundation, the Sacerdote Fund and the PepsiCo Foundation for Prostate Cancer.

PII: S0022-5347(07)01986-6

doi:10.1016/j.juro.2007.08.015

The Journal of Urology
Volume 178, Issue 6 , Pages 2378-2384, December 2007

Article Tools

* Image Usage & Resolution